Kura Historical Income Statement
| KURA Stock | USD 18.59 0.42 2.21% |
Historical analysis of Kura Oncology income statement accounts such as Selling General Administrative of 53.1 M can show how well Kura Oncology performed in making a profits. Evaluating Kura Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kura Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Kura Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kura Oncology is a good buy for the upcoming year.
Kura |
About Kura Income Statement Analysis
Kura Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kura Oncology shareholders. The income statement also shows Kura investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Kura Oncology Income Statement Chart
Kura Oncology Income Statement is one of the three primary financial statements used for reporting Kura's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Kura Oncology revenue and expense. Kura Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Kura Oncology's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 173.2 M, whereas Operating Income is projected to grow to (157.5 M). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kura Oncology. It is also known as Kura Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Kura Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 173.2 M, whereas Operating Income is projected to grow to (157.5 M).
Kura Oncology income statement Correlations
Click cells to compare fundamentals
Kura Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kura Oncology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 67.5M | 91.9M | 131.3M | 139.9M | 165.8M | 174.1M | |
| Operating Income | (67.5M) | (92.1M) | (131.8M) | (140.6M) | (165.8M) | (157.5M) | |
| Ebit | (67.5M) | (92.1M) | (131.8M) | (140.6M) | (165.8M) | (157.5M) | |
| Ebitda | (67.5M) | (91.9M) | (131.3M) | (139.9M) | (165.0M) | (156.7M) | |
| Total Operating Expenses | 67.5M | 91.9M | 131.3M | 139.9M | 165.0M | 173.2M | |
| Income Before Tax | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (152.6M) | (145.0M) | |
| Net Income | (63.1M) | (89.4M) | (129.9M) | (136.1M) | (152.6M) | (145.0M) | |
| Interest Expense | 580K | 578K | 414K | 229K | 1.5M | 1.6M | |
| Selling General Administrative | 19.7M | 31.5M | 46.5M | 47.1M | 50.6M | 53.1M | |
| Total Other Income Expense Net | 4.3M | 2.5M | 1.4M | 4.8M | 13.2M | 13.8M | |
| Net Income From Continuing Ops | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (143.0M) | (135.8M) | |
| Net Income Applicable To Common Shares | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (122.3M) | (116.1M) | |
| Depreciation And Amortization | 10.0 | 194K | 558K | 759K | 849K | 891.5K | |
| Research Development | 47.8M | 60.4M | 84.7M | 92.8M | 115.2M | 121.0M | |
| Income Tax Expense | (4.9M) | (194K) | (558K) | 229K | 206.1K | 216.4K | |
| Interest Income | 4.7M | 2.8M | 1.2M | 4.3M | 12.6M | 13.3M | |
| Non Operating Income Net Other | 4.9M | 2.9M | 1.2M | 4.3M | 4.9M | 2.8M | |
| Net Interest Income | 4.1M | 2.2M | 792K | 4.0M | 11.2M | 11.8M | |
| Reconciled Depreciation | 12K | 194K | 558K | 759K | 841K | 883.1K |
Kura Oncology Investors Sentiment
The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.